SGLT2-inhibitors are effective and safe in the elderly: The SOLD study

• Main Authors: Maria Elena Lunati (Author), Vincenzo Cimino (Author), Alessandra Gandolfi (Author), Matteo Trevisan (Author), Laura Montefusco (Author), Ida Pastore (Author), Camilla Pace (Author), Nazarena Betella (Author), Giuseppe Favacchio (Author), Monica Bulgheroni (Author), Loredana Bucciarelli (Author), Giulia Massari (Author), Cristina Mascardi (Author), Angela Girelli (Author), Paola Silvia Morpurgo (Author), Franco Folli (Author), Livio Luzi (Author), Marco Mirani (Author), Basilio Pintaudi (Author), Federico Bertuzzi (Author), Cesare Berra (Author), Paolo Fiorina (Author)
• Format: Book
• Published: Elsevier, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and aims: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) may have important benefits for the elderly with type 2 diabetes (T2D), however some safety concerns still limit their use in patients over 70 years of age. The SOLD study (SGLT2i in Older Diabetic patients) is a multicenter st...